IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

Rhea-AI Summary

IceCure Medical, developer of the ProSense® Cryoablation System, announced that CEO Eyal Shamir will present at the A.G.P / Alliance Global Partners' Virtual Healthcare Company Showcase on May 21, 2024. The presentation will cover key achievements, including the completion of the ICE3 breast cancer cryoablation trial, submission of results to the FDA, and a pending De Novo Classification Request for marketing clearance. Additionally, the company will highlight ProSense®'s growing global reach and its efficacy in women's health and interventional oncology. Shamir emphasized the significance of these developments for enhancing shareholder value and accelerating commercial goals in the U.S. market.

Positive

• Completion of the ICE3 breast cancer cryoablation trial.
• Published positive top-line results from the ICE3 trial.
• Submission of the complete dataset to the FDA for review.
• Pending De Novo Classification Request with the FDA for ProSense®.
• Increasing global commercial reach of the ProSense® system.
• Growing body of independent research supporting ProSense®'s efficacy and safety.
• Opportunity to enhance shareholder value through strategic presentations and updates.
• Focus on accelerating commercial goals for ProSense® in the U.S. market.

Negative

• Pending FDA approval, which carries inherent risks and uncertainties.
• Potential delays in obtaining marketing clearance for ProSense®.
• High dependency on FDA's De Novo Classification Request outcome.
• Unspecified financial impacts from pending regulatory and trial outcomes.

CAESAREA, Israel, May 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the Company's CEO, Eyal Shamir, will present via a fireside chat at the A.G.P / Alliance Global Partners' Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 8:20am EDT. Investors may register to view the presentation at the virtual conference through the following LINK.

 

Mr. Shamir will present an update on the latest developments and catalysts for IceCure, including the recently announced results of the ICE3 breast cancer cryoablation trial, its pending De Novo Classification Request with the U.S. Food and Drug Administration ("FDA") for marketing clearance of the ProSense® Cryoablation System for the treatment of patients with early-stage, low risk breast cancer, as well as ProSense®'s increasing global commercial reach and growing body of independent research on the efficacy and safety of ProSense in women's health and interventional oncology.

"This has already been an incredibly productive year for IceCure Medical as we completed the ICE3 study, published positive top line results and submitted the complete dataset to the FDA last month," commented Eyal Shamir, Chief Executive Officer. "These are exciting developments, and the conference allows us to highlight our achievements and share our vision for the next phase upon a successful outcome with the FDA and enhance shareholder value as we accelerate our commercial goals for ProSense in the U.S. market."

About ProSense®

The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

IR Contact:

Email: investors@icecure-medical.com

Michael Polyviou
Phone: 732-232-6914

Todd Kehrli
Phone: 310-625-4462

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-highlight-key-achievements-and-provide-business-overview-at-agp--alliance-global-partners-virtual-healthcare-company-showcase-302149964.html

SOURCE IceCure Medical

FAQ

What is IceCure Medical's latest achievement?

IceCure Medical completed the ICE3 breast cancer cryoablation trial and submitted the results to the FDA.

When is IceCure Medical presenting at the A.G.P / Alliance Global Partners' Virtual Healthcare Company Showcase?

IceCure Medical's CEO, Eyal Shamir, will present on May 21, 2024, at 8:20am EDT.

What is the significance of the ICE3 trial for IceCure Medical?

The ICE3 trial is significant because it showed positive results for ProSense®'s efficacy in treating early-stage, low-risk breast cancer, and its results were submitted to the FDA.

What is the ProSense® Cryoablation System?

ProSense® is a minimally-invasive cryoablation technology developed by IceCure Medical that destroys tumors by freezing, offering an alternative to surgical tumor removal.

Why is IceCure Medical's pending De Novo Classification Request important?

The De Novo Classification Request with the FDA is important as it seeks marketing clearance for ProSense® to treat patients with early-stage, low-risk breast cancer.

How is IceCure Medical expanding its global reach?

IceCure Medical is increasing the global commercial reach of the ProSense® system and gaining more independent research supporting its efficacy and safety.

What are IceCure Medical's future plans?

IceCure Medical plans to enhance shareholder value and accelerate commercial goals for ProSense® in the U.S. market.